Funder: International Association for the Study of Lung Cancer, jointly with the Lung Cancer Foundation of America
Due Dates: January 14, 2027, at 12:00 p.m. MST (Full application) | May 14, 2027 (Review outcome) | July 1, 2027 (Approximate funding start)
Funding Amounts: $100,000 annually for up to two years ($200,000 total), with conditional second-year support
Summary: Supports early-career investigators conducting translational clinical-oncology research to improve lung cancer detection, diagnosis, treatment, and patient care.
Key Information: Applicants must be IASLC members and meet strict academic-rank, career-stage, and prior-funding restrictions.
Description
Jointly funded by the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC), these grants support early-career investigators in translational thoracic oncology. Research must seek an immediate, relevant impact on lung cancer patient care or interpret clinical-trial results at the molecular level to inform future trials. The program aims to improve detection, diagnosis, care, and treatment while reducing the burden of lung cancers.
Research interests include molecular risk assessment, molecular diagnostics, early detection, curative-intent therapy, predictive features for targeted or immune therapies, metastatic disease outcomes, treatment side effects, and causes of non-smoking-related lung cancer. Special consideration goes to projects with near-term patient impact, including prospective clinical trials, improved care access or outcomes, and direct benefits for underrepresented populations.
